Member Info for glasshalfdrunk

Fud, fud, fud...empty vessels and all that

Not on Aim, Bella

GSA short down 0.11% to 0.67% as of today

Shoddy journalism at its worst - ‘might’ and ‘ sources close to the matter’ essentially means I may have just made this up to help a mate! You’d expect better from the FT or maybe not?!

Each deal is different cj

Here is a roundup of their recent financing deals https://www.hcrx.com/news/

Something afoot? or just way oversold?

suspicious minds Elvis? 🤣

Boom would like to know which is his ar$e and which is his elbow? 🤣

Yep Boom07 in the green bin - apologies Boom if you post anything sensible but you obviously used to post a whole load of nonsense! Tuan also in the bin, along with micky and many others - i keep you out of the bin for comedy value Stu - its like th m odern day stocks/pillory except Haywain throws scientific facts at you rather than rotten veg!

Stu

Have you lost the plot?

You said 'I’m very encouraged others here have also ( somewhat belatedly) realized the twisting of facts and science within your posts to promote your bias.'

these belated others must be in my green bin as i havent seen or heard from them.

🤷

RMC

I wish you well , however it seems your posting history doesnt agree with you rhetoric.

Unlike most HEMO investors who despite being underwater actually care about the progress/success of the company you posted in Feb 2025 about your 'succesful' investment

'You're right to be cynical. Bezant is a truly awful company.'

Then just last week you posted - 'For a brief period yesterday I was in profit. Felt kind of odd.' - is that your idea of 'looking good, Really Good?!

I hope BZT comes good for you just as i hope HEMO comes good for its investors and the terminally ill people that will benefit from it one day

If you project some kindness it may come back to you tenfold

£57k not to be sniffed at!

Someone know something?

You're embarassing yourself now RMC 🤣

You're only bitter because you bought on a spike in BZT when the price was 10 times higher than it currently is and have spent years trolling ever since

Hi Dan

The RNS is just a legal requirement at the end of the month if the no. of shares allotted/issued have changed.

We had one at the end of March which wasnt followed by a raise, we had one at the end of may which was followed by a placing - so 50/50?

We all know that Vlad/Hemo need cash - most peoples thinking is August is the crux month of P1 at month 6 and P3 passed 28 days - so its watch this space to see how we get there?

I remain optimistic 🍷

Stu

Why do you keep coming back for beating after beating?

Do you wear a hair-shirt under your clown/troll costume too?

Difficult to make fists when you only have cloven hooves 🤣

Did they steal all the helicopters as well? 🤪🤣

Garicky with your total of 3 posts that began 2 hours ago you must be sooo tired of Sunda

My bet is on a reworked finance package for the drill in due course with no CLN,s

Clarivate had just published an interesting report which is downloadable for free - Avacta even gets a one line mention re their deal with POINT

'Radioligand therapies (RLTs) are ushering in a transformative era for precision oncology, merging decades of nuclear medicine innovation with cutting-edge biotechnology to target cancers with unprecedented specificity. These therapies combine radioactive isotopes with tumor-targeting ligands— such as peptides, antibodies or small molecules—to deliver localized radiation directly to cancer cells while sparing healthy tissue. The resurgence of interest in RLTs, driven by advancements in theranostics (integrated diagnostic and therapeutic agents), has positioned them as a cornerstone of next-generation cancer care. With the global radiopharmaceutical market projected to exceed $13bn over the next decade, the field is witnessing explosive growth fueled by clinical breakthroughs, strategic acquisitions and regulatory momentum.'

'The recent flurry of licensing partnerships, mergers and acquisitions (M&As) and venture capital (VC) financing includes Bristol Myers Squibb Co's $4.1bn acquisition of RayzeBio Inc, AstraZeneca's $2.4bn purchase of Fusion Pharmaceuticals Inc and Eli Lilly and Co's $1.4b nacquisition of POINT Biopharma. These transactions highlight the industry's commitment to expanding their radiopharmaceutical pipelines, as well as the promise of RLTs to truly disrupt cancer treatments. '

'Overall, Novartis is the biggest spender, shelling out approximately $6bn to acquire theranostic expertise and assets, including PLUVICTO, the first targeted RLT containing a radioisotope to make it to market, from Endocyte Inc for $2.1bn. As long-standing radiopharmaceutical leaders, Bayer and Novartis have demonstrated the marketability of RLTs, with PLUVICTO reaching blockbuster status ($1.39bn in sales), a 42% increase from 2023, and LUTATHERA hitting $724m in sales by the end of 2024, a 20% increase from 2023 (Novartis, 2024b). These companies have paved the way for further research and regulatory approvals in the field. Figure 1: PLUVICTO dominates forecasted sales of RLTs Already in the first month of 2025, $2.6bn has been spent in M&As, led by Lantheus Holdings in its acquisition of Evergreen Theragnostics Inc for an estimated $1.0bn and Life Molecular Imaging Ltd (LMI) for an estimated $780m. In the most recent M&A transaction, Telix acquired RLS Inc, the only Joint Commission-accredited radiopharmacy network distributing positron emission tomography (PET), single photon emission computed tomography (SPECT) and therapeutic radiopharmaceuticals, for $250m. As Telix looks to enable distribution of its products worldwide, this further cements its North American manufacturing footprint and presence in the United States.'

Lots of deals have been done, lots more to be done...👍